Optimal chemotherapy for advanced gastric cancer: is there a global consensus? (Q38139297)

29 August 2017

Optimal chemotherapy for advanced gastric cancer: is there a global consensus? (English)

1 reference

29 August 2017

1 reference

Florian Lordick

1

1 reference

29 August 2017

Sylvie Lorenzen

series ordinal

2

1 reference

29 August 2017

Yasuhide Yamada

series ordinal

3

1 reference

29 August 2017

David Ilson

series ordinal

4

1 reference

29 August 2017

19 September 2013

1 reference

29 August 2017

1 reference

29 August 2017

17

1 reference

29 August 2017

2

1 reference

29 August 2017

213-225

1 reference

https://scigraph.springernature.com/pub.10.1007/s10120-013-0297-z

29 August 2017

0 references

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

Is there a role for second-line chemotherapy in advanced gastric cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

Cancer treatment and survivorship statistics, 2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer G

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

Population-based differences in treatment outcome following anticancer drug therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

Her2/neu testing in gastric cancer: evaluating the risk of sampling errors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0297-Z

Phase II study of carboplatin in untreated inoperable advanced stomach cancer

21 January 2018

1 reference

12 December 2020

Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973-2000: increase in the signet ring cell type

1 reference

12 December 2020

Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial

1 reference

12 December 2020

HER2 in gastric cancer: a biomarker with clinical impact, but not without translational challenges

1 reference

12 December 2020

Gastrointestinal cancer: Salvage chemotherapy in gastric cancer--more than a straw?

1 reference

12 December 2020

Chemotherapy for advanced gastric cancer

1 reference

12 December 2020

Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer

1 reference

12 December 2020

Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study.

1 reference

12 December 2020

A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601)

1 reference

12 December 2020

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial

1 reference

12 December 2020

Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group

1 reference

12 December 2020

10.1007/S10120-013-0297-Z

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

1027293934

0 references

Fatcat ID

release_qwfcusmnvvb5tm74bh7ekyhxmm

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qwfcusmnvvb5tm74bh7ekyhxmm

24 November 2022

mapped directly with Wikidata item

1 reference